Pharmafile Logo

The Price of Drugs – The Cost of LIVING

March 17, 2022 |  

With increasing drug prices, what is the true cost to society? (Article written 2nd December 2020)

The pharmaceutical industry has entered a period which will test the most fundamental aspects of its relationship with patients and payors around the world.

I wonder if it has prepared itself for the battle ahead?

By ‘battle’ I mean the constant need to justify the prices of cutting edge medicines that it brings to market. Gone are the days when companies could launch a primary care drug with literally millions of potential patients and charge, say, £250 for a year’s treatment. That was easy. But what if you have a life-saving drug for an ultra-rare disease? You don’t need to be a mathematician to work out that any commercial return on the R&D investment will require a price not in the hundreds of pounds, but in the hundreds of thousands of pounds – and even more.

Indeed there are now many examples of such therapies and earlier this year, the FDA approved a single-injection gene therapy for a rare childhood disorder at a price of over $2 million. This inevitably pushes the debate into philosophical territory and my fear is that this is a debate that the industry can’t win.

Why? Because hard science combined with the need for shareholder reward does not sit comfortably in a philosophical framework. The question of ‘can you put a price on life?’ is centuries old and these recent developments only put a sharper focus on the question, but they don’t provide an answer.

Think of it from another perspective by turning the drug development process on its head. Imagine if you set out on an R&D project, not with the intent of finding a way of repairing a specific genetic fault (almost pure science), but by being asked the following question: “how much are you prepared to commit to your R&D budget to save this child’s live?”

Click here to continue reading this article.

This content was provided by Dice Medical Communications

Company Details

 Latest Content from  Dice Medical Communications 

Early communications in Pharma: How effective pre-approval comms delivers launch success

What communications are required for a successful launch

Science for science sake

Like great works of art, there was no ‘reason’ for certain scientific endeavours, but this ‘just for the sake of it’ philosophy is now delivering tangible benefits. (article written 3rd...

Measurement in Med Comms: Striving for Creative Effectiveness

How to achieve creative success in Med Comms (Article written 6th Jan 2020)

Why testing shouldn't be confined to the lab

Believe it or not, experiments are just as important in marketing as they are in science.

Tactics Smactics: Why Alignment Comes Before Creative Execution

How to use the correct marketing tactics (Article written 13th April 2020)

It takes two - Maximising the client-agency relationship

How to start, build and maintain a great client-agency relationship (Written 3rd March 2021)

Celebrating the new UK rare diseases framework

Dice's take on the importance of the rare diseases framework

What do we really value as a society?

'A third of older people in our society die with dementia. A third.' Will the government invest more to help find a cure? (Article written 14th June 2021).

Could I have a word please...?

Just how important is hard hitting copy?

The Price of Drugs – The Cost of LIVING

With increasing drug prices, what is the true cost to society? (Article written 2nd December 2020)